Clinical Research Directory

Inclusion Criteria: * Pathologically confirmed nasopharyngeal carcinoma scheduled for curative intensity-modulated radiation therapy (IMRT), with or without concurrent chemotherapy. * Age between 18 and 75 years. * No previous history of head and neck radiotherapy. * Intact tympanic membranes bilaterally at baseline, with no history of middle ear surgery (including tympanostomy tube placement). * Willing to comply with all study procedures, including nasal spray use, audiological examinations, and follow-up visits. * No use of systemic or topical corticosteroids, antihistamines, or decongestants within 14 days prior to randomization. * All inclusion criteria must be met for participation Exclusion Criteria: * Diagnosed with complete conductive hearing loss or ossicular chain fixation. * Scheduled to undergo tympanostomy tube placement, tympanotomy, or other middle ear surgery prior to randomization. * Unlikely to complete the 12-month follow-up (e.g., planned relocation, poor compliance). * Presence of respiratory conditions requiring treatment with nasal corticosteroids. * Known allergy or hypersensitivity to nasal corticosteroids (especially triamcinolone acetonide or its excipients). * History of severe mental illness, cognitive impairment, or substance abuse that may affect compliance. * Pregnant or lactating women, or women of childbearing potential unwilling to use effective contraception. * Participation in other investigational drug clinical trials within the past 3 months. * Deemed unsuitable for the trial by the investigator (e.g., severe septal deviation, chronic rhinosinusitis requiring systemic treatment, or poorly controlled diabetes). * Any subject who meets any of the above exclusion criteria at baseline will be excluded from the study.